Astellas CCO: Pharmaceutical reform will scare investments away from Europe

According to the European Commission, the reform aims to make Europe a more attractive place to invest in R&D.
Photo: Kota Kiriyama/AP/Ritzau Scanpix
Photo: Kota Kiriyama/AP/Ritzau Scanpix

An impending pharmaceutical reform in Europe could end up driving investment away from the continent, warns Claus Zieler, Chief Commercial Officer of Japan’s Astellas and board member of the industry association EFPIA, according to Endpoints

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading